Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 5Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Lymphoma, Non-Hodgkin 3Lymphoma 3Ovarian Neoplasms 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Carcinoma, Ovarian Epithelial 2Blast Crisis 2Shwachman-Diamond Syndrome 1Primary Immunodeficiency Diseases 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Neuroblastoma 1Neoplasms, Plasma Cell 1Macrophage Activation Syndrome 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1High Risk Myeloid Malignancies 1Hemoglobinopathies 1

Interventions

Transplantation Conditioning 1Thiotepa 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × High Risk Myeloid Malignancies × Thiotepa × Clear all
NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡